Estradiol increases platelet aggregation in PlA1/A1 individuals

Konstantinos D. Boudoulas, Christine Roos Montague, Pascal Goldschmidt-Clermont, Glen E. Cooke

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The platelet glycoprotein IIb/IIIa receptor is a key mediator of platelet aggregation and intracoronary thrombosis. Studies have suggested that hormone replacement therapy (HRT) may increase coronary events in postmenopausal women. Objectives: We sought to characterize the relationship between the estrogen concentration expected in HRT and platelet aggregation. Design and Results: Platelet aggregation studies were performed using epinephrine on 30 healthy individuals (15 PlA1/A1 and 15 PlA1/A2) before and after incubation with β-estradiol (E2) (10-11 mol/L). The effect of E2 10-11 mol/L on PlA1/A1 platelets demonstrated a significant increase (P = .03) in aggregation compared with baseline. In contrast, with the same concentration of E2, aggregation of PlA1/A2 platelets decreased significantly compared with baseline (P < .0001). Conclusions: Estrogen concentration similar to that expected in HRT resulted in an increase in platelet aggregation in PlA1/A1 individuals, but not in PlA1/A2 individuals. The data may provide further insight for the increase in coronary events seen in HRT clinical trials and suggest that further evaluation is needed to better define the role of pharmacogenetics in HRT.

Original languageEnglish
Pages (from-to)136-139
Number of pages4
JournalAmerican Heart Journal
Volume152
Issue number1
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Hormone Replacement Therapy
Platelet Aggregation
Estradiol
varespladib methyl
Estrogens
Blood Platelets
Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Pharmacogenetics
Epinephrine
Thrombosis
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Boudoulas, K. D., Montague, C. R., Goldschmidt-Clermont, P., & Cooke, G. E. (2006). Estradiol increases platelet aggregation in PlA1/A1 individuals. American Heart Journal, 152(1), 136-139. https://doi.org/10.1016/j.ahj.2005.07.036

Estradiol increases platelet aggregation in PlA1/A1 individuals. / Boudoulas, Konstantinos D.; Montague, Christine Roos; Goldschmidt-Clermont, Pascal; Cooke, Glen E.

In: American Heart Journal, Vol. 152, No. 1, 01.07.2006, p. 136-139.

Research output: Contribution to journalArticle

Boudoulas, KD, Montague, CR, Goldschmidt-Clermont, P & Cooke, GE 2006, 'Estradiol increases platelet aggregation in PlA1/A1 individuals', American Heart Journal, vol. 152, no. 1, pp. 136-139. https://doi.org/10.1016/j.ahj.2005.07.036
Boudoulas KD, Montague CR, Goldschmidt-Clermont P, Cooke GE. Estradiol increases platelet aggregation in PlA1/A1 individuals. American Heart Journal. 2006 Jul 1;152(1):136-139. https://doi.org/10.1016/j.ahj.2005.07.036
Boudoulas, Konstantinos D. ; Montague, Christine Roos ; Goldschmidt-Clermont, Pascal ; Cooke, Glen E. / Estradiol increases platelet aggregation in PlA1/A1 individuals. In: American Heart Journal. 2006 ; Vol. 152, No. 1. pp. 136-139.
@article{73d482caa0d446659f0f37f1f94d3891,
title = "Estradiol increases platelet aggregation in PlA1/A1 individuals",
abstract = "Background: The platelet glycoprotein IIb/IIIa receptor is a key mediator of platelet aggregation and intracoronary thrombosis. Studies have suggested that hormone replacement therapy (HRT) may increase coronary events in postmenopausal women. Objectives: We sought to characterize the relationship between the estrogen concentration expected in HRT and platelet aggregation. Design and Results: Platelet aggregation studies were performed using epinephrine on 30 healthy individuals (15 PlA1/A1 and 15 PlA1/A2) before and after incubation with β-estradiol (E2) (10-11 mol/L). The effect of E2 10-11 mol/L on PlA1/A1 platelets demonstrated a significant increase (P = .03) in aggregation compared with baseline. In contrast, with the same concentration of E2, aggregation of PlA1/A2 platelets decreased significantly compared with baseline (P < .0001). Conclusions: Estrogen concentration similar to that expected in HRT resulted in an increase in platelet aggregation in PlA1/A1 individuals, but not in PlA1/A2 individuals. The data may provide further insight for the increase in coronary events seen in HRT clinical trials and suggest that further evaluation is needed to better define the role of pharmacogenetics in HRT.",
author = "Boudoulas, {Konstantinos D.} and Montague, {Christine Roos} and Pascal Goldschmidt-Clermont and Cooke, {Glen E.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1016/j.ahj.2005.07.036",
language = "English",
volume = "152",
pages = "136--139",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Estradiol increases platelet aggregation in PlA1/A1 individuals

AU - Boudoulas, Konstantinos D.

AU - Montague, Christine Roos

AU - Goldschmidt-Clermont, Pascal

AU - Cooke, Glen E.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Background: The platelet glycoprotein IIb/IIIa receptor is a key mediator of platelet aggregation and intracoronary thrombosis. Studies have suggested that hormone replacement therapy (HRT) may increase coronary events in postmenopausal women. Objectives: We sought to characterize the relationship between the estrogen concentration expected in HRT and platelet aggregation. Design and Results: Platelet aggregation studies were performed using epinephrine on 30 healthy individuals (15 PlA1/A1 and 15 PlA1/A2) before and after incubation with β-estradiol (E2) (10-11 mol/L). The effect of E2 10-11 mol/L on PlA1/A1 platelets demonstrated a significant increase (P = .03) in aggregation compared with baseline. In contrast, with the same concentration of E2, aggregation of PlA1/A2 platelets decreased significantly compared with baseline (P < .0001). Conclusions: Estrogen concentration similar to that expected in HRT resulted in an increase in platelet aggregation in PlA1/A1 individuals, but not in PlA1/A2 individuals. The data may provide further insight for the increase in coronary events seen in HRT clinical trials and suggest that further evaluation is needed to better define the role of pharmacogenetics in HRT.

AB - Background: The platelet glycoprotein IIb/IIIa receptor is a key mediator of platelet aggregation and intracoronary thrombosis. Studies have suggested that hormone replacement therapy (HRT) may increase coronary events in postmenopausal women. Objectives: We sought to characterize the relationship between the estrogen concentration expected in HRT and platelet aggregation. Design and Results: Platelet aggregation studies were performed using epinephrine on 30 healthy individuals (15 PlA1/A1 and 15 PlA1/A2) before and after incubation with β-estradiol (E2) (10-11 mol/L). The effect of E2 10-11 mol/L on PlA1/A1 platelets demonstrated a significant increase (P = .03) in aggregation compared with baseline. In contrast, with the same concentration of E2, aggregation of PlA1/A2 platelets decreased significantly compared with baseline (P < .0001). Conclusions: Estrogen concentration similar to that expected in HRT resulted in an increase in platelet aggregation in PlA1/A1 individuals, but not in PlA1/A2 individuals. The data may provide further insight for the increase in coronary events seen in HRT clinical trials and suggest that further evaluation is needed to better define the role of pharmacogenetics in HRT.

UR - http://www.scopus.com/inward/record.url?scp=33745658435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745658435&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2005.07.036

DO - 10.1016/j.ahj.2005.07.036

M3 - Article

VL - 152

SP - 136

EP - 139

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -